This study is in progress, not accepting new patients

MMRF Molecular Profiling Protocol

a study on Multiple Myeloma Plasma Malignancy Neoplasms

Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at San Francisco, California and other locations
Dates
study started
completion around

Description

Summary

This protocol is now being used as screening for the MyDRUG study

Official Title

Clinical-grade Molecular Profiling of Patients With Multiple Myeloma and Related Plasma Cell Malignancies

Details

Here we propose an "integrative sequencing approach" utilizing a 1500 gene exome comparative analysis between multiple myeloma or related plasma cell malignancies and normal cells coupled to capture transcriptome sequencing to provide a nearly comprehensive landscape of the genetic alterations for the purpose of identifying informative and/or actionable mutations in patients with multiple myeloma and plasma cell malignancies. The approach will enable the detection of point mutations, insertions/deletions, gene fusions and rearrangements, amplifications/deletions, and outlier expressed genes among other classes of alterations.

Keywords

Multiple Myeloma, Plasma Malignancy, genetic sequencing, relapsed, Plasma Cell Neoplasms, Neoplasms

Eligibility

You can join if…

Open to people ages 18 years and up

  1. Patients must have a diagnosis of multiple myeloma or related malignancy
  2. Patients are undergoing standard of care bone marrow aspirates
  3. Patients (male or female) from any race or ethnicity must be at least 18 years of age at the time of registration.
  4. Procedure-specific signed informed consent form prior to initiation of any study-related procedures.

You CAN'T join if...

  1. It is the enrolling study physician's discretion to decide if a patient is not fit enough to undergo a bone marrow aspirate.
  2. Patients who are incarcerated are not eligible to participate.
  3. Women who are pregnant
  4. Patients who have had another malignancy within the last five (5) years (except for basal or squamous cell carcinoma, or in situ cancer of the cervix) where there is a possibility to contaminate the bone marrow aspirate.

Locations

  • UCSF Medical Center
    San Francisco California 94143 United States
  • City of Hope
    Duarte California 91010 United States

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Multiple Myeloma Research Foundation
ID
NCT02884102
Study Type
Observational
Participants
Expecting 1000 study participants
Last Updated